PANTHER - P2Y12 inhibitor or Aspirin moNoTHERapy as secondary prevention in patients with coronary artery disease

29 August 2025 (07:00 - 18:00)

Organised by:

Sign in for access options

Sign in for access options

About the speaker

Professor Marco Valgimigli

Cardiocentro Ticino Institute, Lugano (Switzerland)

3 More presentations in this session

Presentation thumbnail

MACROS-2: RCT of ESC 0/1 versus 0/3 hour ADP for suspected ACS

Doctor J. Hatherley (Liverpool, GB)

Presentation thumbnail

Complete revascularisation versus usual care in non-STEMI with multivessel disease: results from the SLIM study

Mr T. Pustjens (Maastricht, NL)

Presentation thumbnail

PIONEER IV trial primary report

Professor P. Serruys (Galway, IE)

Access the full session

Session thumbnail

Late-Breaking Clinical Trials: coronary artery disease and interventions

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025

You may be interested in

Congress Presentation

Abbreviated versus standard dual antiplatelet therapy time after PCI in high bleeding risk patients with acute coronary syndrome - a report from the SWEDEHEART registry

Congress Presentation

Ticagrelor or Clopidogrel to reduce ischemic events after Percutaneous Coronary Intervention in chronic coronary syndrome in clopidogrel naive patient: the ALPHEUS Naive sub-study.

Congress Presentation

Clopidogrel vs. aspirin in the chronic maintenance period following percutaneous coronary intervention in high thrombotic and high bleeding risk patients:sub-analysis of the HOST-EXAM Extended study

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources